An international controlled clinical study published in The New England Journal of Medicine demonstrates that liquid biopsy can help identify which p1
Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
Reveal Genomics’ first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.
